BIO Double Helix Sponsor
Sponsors

Company Profile

Celleration, Inc.

Wound
Gene/Cell Therapy
Drug Delivery

10250 Valley View Rd. , Suite 137
Eden Prairie, Minnesota 55391
USA
www.celleration.com 		Incorporated in 1999
45 Employees 		Privately Held

This Year's Highlights

  • FDA approval through DeNovo Pathway
  • Second FDA approval - 1st to market with "To promote wound healing" and not "may"
  • Three Medicaid States providing reimbursement for technology and AMA has deemed the technology needs and justifies a category III code

Anticipated Highlights

  • Pain and narcotic reduction indication from the FDA
  • Incremental Medicare Payment
  • Marketing collateral regarding bioburden reduction in colinized wounds

Corporate Mission

: Celleration?, Inc. is a proprietary ultrasound based development stage medical device company that is clinically validating a novel therapeutic treatment for chronic wounds by proactively conducting a large pivotal clinical trial for safety and efficacy. Celleration?s core technology is a patented non-imaging, non-contact ultrasound system called MIST Therapy System (?MIST?). The Company has demonstrated the technology?s ability to accelerate the healing of chronic wounds through stimulating healthy cells throughout all three phases of the healing process, including management of bacteria. Due to these mechanisms of action, the Company believes that a broader market application for the technology exists beyond chronic wound management.